← Back to Discover
Cormorant Asset Management, LP
Period ended Jun 30, 2026 · Latest filing Aug 14, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Jun 30, 2026: $1,951,406,063
More quarters will appear as history becomes available.
Top holdings
Top 10 at Jun 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- PRAXIS PRECISION MEDICINES I · COM NEW · 74006W207 · shares: $214,265,600
- BRIDGEBIO ONCOLOGY THERAPEUT · COM NEW · 107924102 · shares: $136,234,886
- PARABILIS MEDICINES INC · COM · 698955101 · shares: $126,329,300
- RAPPORT THERAPEUTICS INC · COM · 75383L102 · shares: $110,738,900
- ERASCA INC · COM · 29479A108 · shares: $109,920,000
- EDGEWISE THERAPEUTICS INC · COM · 28036F105 · shares: $101,981,300
- EYEPOINT INC · COM NEW · 30233G209 · shares: $100,100,000
- ALUMIS INC · COM · 022307102 · shares: $92,456,671
- ABIVAX SA · SPONSORED ADS · 00370M103 · shares: $89,950,500
- DIANTHUS THERAPEUTICS INC · COM · 252828108 · shares: $73,110,000
Reported holdings
50 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES I | COM NEW | 74006W207 | — | 640,000 shares | $214,265,600 |
| BRIDGEBIO ONCOLOGY THERAPEUT | COM NEW | 107924102 | — | 17,878,594 shares | $136,234,886 |
| PARABILIS MEDICINES INC | COM | 698955101 | — | 4,615,612 shares | $126,329,300 |
| RAPPORT THERAPEUTICS INC | COM | 75383L102 | — | 2,657,521 shares | $110,738,900 |
| ERASCA INC | COM | 29479A108 | — | 6,000,000 shares | $109,920,000 |
| EDGEWISE THERAPEUTICS INC | COM | 28036F105 | — | 2,510,000 shares | $101,981,300 |
| EYEPOINT INC | COM NEW | 30233G209 | — | 7,000,000 shares | $100,100,000 |
| ALUMIS INC | COM | 022307102 | — | 3,285,596 shares | $92,456,671 |
| ABIVAX SA | SPONSORED ADS | 00370M103 | — | 675,000 shares | $89,950,500 |
| DIANTHUS THERAPEUTICS INC | COM | 252828108 | — | 750,000 shares | $73,110,000 |
| BRIGHT MINDS BIOSCIENCES INC | COM NEW | 10919W405 | — | 900,000 shares | $63,180,000 |
| MOONLAKE IMMUNOTHERAPEUTICS | CLASS A ORD | 61559X104 | — | 3,205,433 shares | $62,409,781 |
| BIOAGE LABS INC | COM | 09077V100 | — | 2,390,605 shares | $58,593,729 |
| ORUKA THERAPEUTICS INC | COM | 687604108 | — | 533,340 shares | $50,757,968 |
| ADLAI NORTYE LTD | SPONSORED ADS | 00704R109 | — | 3,978,229 shares | $45,749,634 |
| BRIDGEBIO PHARMA INC | COM | 10806X102 | — | 550,000 shares | $40,964,000 |
| TANGO THERAPEUTICS INC | COM | 87583X109 | — | 1,300,000 shares | $40,638,000 |
| BIOHAVEN LTD | COM | G1110E107 | — | 2,610,000 shares | $38,836,800 |
| AGOMAB THERAPEUTICS NV | SPONSORED ADS | 00860C102 | — | 2,465,348 shares | $32,000,217 |
| MBX BIOSCIENCES INC | COM | 55287L101 | — | 550,000 shares | $30,360,000 |
| CLIMB BIO INC | COM | 28658R106 | — | 2,106,000 shares | $27,462,240 |
| OLEMA PHARMACEUTICALS INC | COM | 68062P106 | — | 2,150,000 shares | $26,896,500 |
| DAMORA THERAPEUTICS INC | COM | 36322Q206 | — | 1,000,000 shares | $26,010,000 |
| PHARVARIS N V | COM | N69605108 | — | 750,000 shares | $25,935,000 |
| CORBUS PHARMACEUTICALS HLDGS | COM NEW | 21833P301 | — | 2,344,971 shares | $21,995,828 |
| SPYRE THERAPEUTICS INC | COM NEW | 00773J202 | — | 225,000 shares | $19,975,500 |
| DEFINIUM THERAPEUTICS INC | COM SHS | 24477V105 | — | 400,000 shares | $18,816,000 |
| NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | N62509109 | — | 500,000 shares | $16,945,000 |
| ROIVANT SCIENCES LTD | SHS | G76279101 | — | 475,000 shares | $16,810,250 |
| CABALETTA BIO INC | COM | 12674W109 | — | 5,000,000 shares | $15,550,000 |
| HELIX ACQUISITION CORP III | USD CL A ORD SHS | G4444S107 | — | 1,297,500 shares | $13,805,400 |
| ASCENDIS PHARMA A/S | ORD SHS | K08588103 | — | 50,000 shares | $13,336,000 |
| KAILERA THERAPEUTICS INC | COMMON STOCK | 482931102 | — | 550,000 shares | $12,116,500 |
| INSMED INC | COM PAR $.01 | 457669307 | — | 75,000 shares | $7,996,500 |
| FAETH THERAPEUTICS INC | COM NEW | 81728A207 | — | 1,028,242 shares | $7,655,550 |
| ENLIVEN THERAPEUTICS INC | COM | 29337E102 | — | 150,000 shares | $7,612,500 |
| TARSUS PHARMACEUTICALS INC | COM | 87650L103 | — | 100,000 shares | $6,294,000 |
| IBIO INC | COM NEW | 451033708 | — | 3,570,000 shares | $6,247,500 |
| CRINETICS PHARMACEUTICALS IN | COM | 22663K107 | — | 125,000 shares | $4,677,500 |
| ARCUTIS BIOTHERAPEUTICS INC | COM | 03969K108 | — | 175,000 shares | $4,588,500 |
| ARROWHEAD PHARMACEUTICALS IN | COM | 04280A100 | — | 50,000 shares | $4,075,500 |
| STRUCTURE THERAPEUTICS INC | SPONSORED ADS | 86366E106 | — | 75,000 shares | $4,025,250 |
| RESEARCH ALLIANCE CORP III | ORD SHS CL A | G75226103 | — | 370,000 shares | $3,959,000 |
| COGENT BIOSCIENCES INC | COM | 19240Q201 | — | 100,000 shares | $3,870,000 |
| ALTIMMUNE INC | COM NEW | 02155H200 | — | 1,250,000 shares | $3,800,000 |
| AMYLYX PHARMACEUTICALS INC | COM | 03237H101 | — | 200,000 shares | $3,592,000 |
| ODYSSEY THERAPEUTICS INC | COMMON STOCK | 67613T104 | — | 175,000 shares | $3,274,250 |
| VAXCYTE INC | COM | 92243G108 | — | 50,000 shares | $2,906,500 |
| BOUNDLESS BIO INC | COM | 10170A100 | — | 1,000,000 shares | $2,500,000 |
| QUINCE THERAPEUTICS INC | COM | 22053A305 | — | 5,498 shares | $100,009 |